GOVXNasdaqPharmaceutical PreparationsFiscal year ends December 31
GeoVax Labs, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 27, 2026
$0.23−0.01 (-4.53%)
Close on Oct 19, 2026
- Market cap
- $1.04M
- P/E (TTM)
- –
- Dividend yield
- –
GeoVax Labs statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | GeoVax Labs | Industry median |
|---|---|---|
| Market Cap | $1.68M | $166.30M |
| Enterprise Value | -$1.47M | $87.12M |
| PB Ratio | 0.95 | 2.03 |
| P/TBV Ratio | 0.95 | 2.31 |
Income (trailing twelve months)
| Measure | GeoVax Labs | Industry median |
|---|---|---|
| Revenue | $0 | $57.94M |
| Operating Income | -$20.53M | -$21.49M |
| Net Income | -$20.43M | -$22.46M |
| EBITDA | -$20.47M | -$17.14M |
Returns
| Measure | GeoVax Labs | Industry median |
|---|---|---|
| Return on Equity (ROE) | -891.6% | -53.2% |
| Return on Assets (ROA) | -408.8% | -41.0% |
| Return on Capital Employed (ROCE) | -1063.6% | -38.0% |
Growth
| Measure | GeoVax Labs | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -100.0% | 6.01% |
| Revenue Growth (3Y CAGR) | 212.5% | 2.25% |
| Revenue Growth (5Y CAGR) | 6.42% | 6.42% |
Balance sheet
| Measure | GeoVax Labs | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $3.14M | $62.64M |
| Net Cash (Debt) | $3.14M | $15.77M |
| Net Cash Per Share | $0.43 | $0.66 |
| Equity (Book Value) | $1.76M | $48.61M |
| Book Value Per Share | $0.24 | $1.36 |
| Tangible Book Value | $1.76M | $23.01M |
| Working Capital | $1.46M | $75.09M |
Financial position
| Measure | GeoVax Labs | Industry median |
|---|---|---|
| Current Ratio | 1.54 | 3.30 |
| Quick Ratio | 1.16 | 2.39 |
Cash flow (trailing twelve months)
| Measure | GeoVax Labs | Industry median |
|---|---|---|
| Operating Cash Flow | -$18.37M | -$12.39M |
| Capital Expenditures | $0 | -$1.07M |
| Free Cash Flow | -$18.37M | -$20.34M |
| FCF Per Share | -$2.49 | -$0.42 |
Efficiency
| Measure | GeoVax Labs | Industry median |
|---|---|---|
| Asset Turnover | 0.00 | 0.38 |
| Revenue Per Employee | $0 | $398.96K |
| Profits Per Employee | -$1.08M | -$705.27K |
| Employee Count | 19 | 74 |
Dividends and yields
| Measure | GeoVax Labs | Industry median |
|---|---|---|
| Earnings Yield | -1218.4% | -22.8% |
| FCF Yield | -1095.7% | -9.02% |
Shares
| Measure | GeoVax Labs | Industry median |
|---|---|---|
| Shares Outstanding | 7,369,240 | 58,139,000 |
| Shares Change (QoQ) | 161.5% | 0.54% |
| Float | 7,169,600 | 49,154,900 |
| Shares Held by Insiders | 2.71% | 11.6% |
| Shares Held by Institutions | 6.69% | 59.4% |
Taxes
| Measure | GeoVax Labs | Industry median |
|---|---|---|
| Income Tax | $0 | $89.00K |
Scores
| Measure | GeoVax Labs | Industry median |
|---|---|---|
| Altman Z-Score | -62.27 | -0.27 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from GeoVax Labs's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.